Moderna CEO Stephane Bancel discusses when to expect booster shots.
Moderna’s stock cemented its position as the top performer in the S&P 500 for 2021, rising another 7.5% on Tuesday ahead of a meeting between the White House and the COVID-19 Response Team set for today in which next steps for boosters are expected to be discussed.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| MRNA | MODERNA, INC. | 401.86 | +28.00 | +7.49% |
The Centers for Disease Control and Prevention has administered 357,894,995 million doses through Aug. 16, with Pfizer-BioNTech leading Moderna in both administered and delivered doses.
Despite the lead, Moderna stock has locked in annual gains of more than 285%, making it the top annual performer for the broadest measure of the U.S. stock market, even with a slight pullback from hitting its high of $497.17 per share.
WALMART DOUBLES PAYOUTS FOR VACCINATED WORKERS
CLICK HERE TO READ MORE ON FOX BUSINESS
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| PFE | PFIZER INC. | 50.42 | +1.51 | +3.09% |
| BNTX | BIONTECH SE | 366.27 | +23.17 | +6.75% |
Moderna CEO Stephane Bancel told FOX Business earlier this month the company is on track to deliver 1 billion doses this year, with even higher expectations for 2022 depending on confirmed clinical dosages.
“It would be between 2 and 3 billion doses, so I expect we would be able to double the output next year, maybe even triple it” he said.
Additionally, Bancel discussed the company’s improving balance sheet.
“We are now sitting on $12.2 billion of cash,” he noted, adding that “the board authorized a share buyback of up to $1 billion” as the company reported quarterly results.
Steelmaker Nucor is the S&P 500’s second-best performer, with annual gains of 125%.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| NUE | NUCOR CORP. | 119.57 | -4.71 | -3.79% |
